Literature DB >> 3912694

[Chemotherapy of advanced ovarian cancer. Göttingen-Hannover studies].

H Kühnle, J Hilfrich.   

Abstract

Patients with ovarian carcinoma stages III and IV were treated with cis-platin (P), adriamycin (A) and cyclophosphamide (C). The total rate of remission in group PC (n = 58) was 86% (CR = 55%), in group PA (n = 48) 65% (CR = 48%) and in group PAC (n = 43) 63% (CR 47%). The number of cycles administered were 8 in PA and PAC, and 5 in PC. Half of the patients survived 18 months (PA), 19 months (PAC) and 21 months (PC) without signs of progression with a survival time of 25 months (PA), 27 months (PAC) and 29 months (PC). In patients who had received primary PA therapy, secondary treatment with combined CPC was carried out. Rate of remission 56%. Treosulphan after PC resulted in 14% remissions, etoposid after CP (n = 38) 11 (29%) remissions.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3912694     DOI: 10.1159/000215690

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  1 in total

1.  Carboplatin/etoposide as first-line chemotherapy in advanced ovarian carcinoma: a pilot study.

Authors:  W Eiermann; W Achterrath; L Lenaz; H Hepp
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.